ArticleLeukemia2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.
Abstract readLetter
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.Blood advances · 2025Trial
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms.British journal of haematology · 2025Article
- Review
- Frontline treatment options for higher-risk MDS: can we move past azacitidine?Hematology. American Society of Hematology. Education Program · 2023Article
- Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.Leukemia · 2023Article
- AML classification in the year 2023: How to avoid a Babylonian confusion of languages.Leukemia · 2023Article
- Are We Ready For "Triplet" Therapy in Higher-Risk MDS?Clinical hematology international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
49 authors.
Amer M Zeidan *Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
Jan Philipp Bewersdorf *Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3352-0902
Rena BucksteinOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada.
Mikkael A SekeresSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-2009-6524
David P SteensmaNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Uwe PlatzbeckerLeipzig University Hospital, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1863-3239
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8980-3202
Jacqueline BoultwoodBlood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-4330-2928
Rafael BejarDivision of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5603-4598
John M BennettHematopathology Division, Departments of Pathology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Uma BorateDivision of Hematology, Department of Internal Medicine, James Cancer Center, Ohio State University, Columbus, OH, USA.
Andrew M BrunnerLeukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Hetty CarrawayLeukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-5241-3614
Jane E ChurpekDepartment of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA.
Naval G DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7103-373X
Matteo Della PortaDepartment of Biomedical Sciences, Humanitas Clinical and Research Center & Humanitas University, Milan, Italy.
Amy E DeZernJohns Hopkins Sidney Kimmel Comprehensive Cancer Centre, Baltimore, MD, USA.
Fabio EfficaceItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Pierre FenauxHôpital Saint Louis, Paris, France.
Maria E FigueroaSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Peter GreenbergDivision of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Elizabeth A GriffithsRoswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID http://orcid.org/0000-0002-0288-8248
Stephanie HaleneSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2737-9810
Robert P HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7753-0697
Christopher S HouriganLaboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6189-8067
Nina KimNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1809-0417
Tae Kon KimDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Rami S KomrokjiDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-1876-5269
Vijay KutchrooEvergrande Center for Immunologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Alan F ListDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Richard F LittleDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4091-1699
Ravi MajetiDivision of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5814-0984
Aziz NazhaDepartment of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Stephen D NimerSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-2439-7586
Olatoyosi OdenikeThe University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Eric PadronDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-4707-7916
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6998-662X
Gail J RobozWeill Cornell Medical College, New York, NY, USA.
David A SallmanDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-0504-8233
Guillermo SanzHematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Health Research Institute La Fe, Valencia, Spain; and CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0002-2767-8191
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Daniel T StarczynowskiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0002-5771-7462
Justin TaylorSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-4407-6325
Zhuoer XieDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-1266-9804
Mina XuDepartments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-9513-245X
Michael R SavonaDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-3763-5504
Andrew H WeiPeter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Omar Abdel-WahabDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Valeria SantiniUniversity of Florence Medical School, Florence, Italy.ORCID http://orcid.org/0000-0002-5439-2172
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteMyelodysplastic SyndromesMyeloproliferative DisordersNeoplasmsHumans
Identifiers
PMID
36266326What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.